Loading...

SOHO 2026 Annual Meeting

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters

Showing 1,267 results.

Thumbnail for Progressive Multifocal Leukoencephalopathy in Chronic Lymphocytic Leukemia During Venetoclax-Obinutuzumab Therapy: A Rare but Fatal Complication

CLL - 447

Progressive Multifocal Leukoencephalopathy in Chronic Lymphocytic Leukemia During Venetoclax-Obinutuzumab Therapy: A Rare but Fatal Complication

Nour Haidar

Poster Presenter: Nour Haidar

Thumbnail for Comparative Efficacy and Safety of Pirtobrutinib Versus Covalent BTK Inhibitors in Treatment-Naοve Chronic Lymphocytic Leukemia: A Systematic Review and Bayesian Network Meta-Analysis

CLL - 450

Comparative Efficacy and Safety of Pirtobrutinib Versus Covalent BTK Inhibitors in Treatment-Naοve Chronic Lymphocytic Leukemia: A Systematic Review and Bayesian Network Meta-Analysis

Pakeeza Saif

Poster Presenter: Pakeeza Saif

Thumbnail for Real-World Clinical Outcomes of Targeted Therapy in a Pakistani Cohort of Chronic Lymphocytic Leukemia

CLL - 465

Real-World Clinical Outcomes of Targeted Therapy in a Pakistani Cohort of Chronic Lymphocytic Leukemia

Munira Borhany

Poster Presenter: Munira Borhany

Thumbnail for Real-World Comparative Analysis of Treatment Discontinuation (TD) with Covalent Bruton Tyrosine Kinase Inhibitors (cBTKis) in First-Line (1L) Chronic Lymphocytic Leukemia (CLL)

CLL - 476

Real-World Comparative Analysis of Treatment Discontinuation (TD) with Covalent Bruton Tyrosine Kinase Inhibitors (cBTKis) in First-Line (1L) Chronic Lymphocytic Leukemia (CLL)

Derrick van Beuge

Poster Presenter: Derrick van Beuge

Thumbnail for How Many Lines of Therapy Do Patients With CLL/SLL Receive in Routine Clinical Practice in the United States? Real-World Evidence From the Targeted Therapy Era

CLL - 560

How Many Lines of Therapy Do Patients With CLL/SLL Receive in Routine Clinical Practice in the United States? Real-World Evidence From the Targeted Therapy Era

Deborah M. Stephens

Poster Presenter: Deborah M. Stephens

Thumbnail for Impact of Type 2 Diabetes on Cardiovascular Toxicity, Infectious Complications, and Survival Among Patients With Chronic Lymphocytic Leukemia Treated With BTK Inhibitors: A Propensity-Matched TriNetX Analysis

CLL - 580

Impact of Type 2 Diabetes on Cardiovascular Toxicity, Infectious Complications, and Survival Among Patients With Chronic Lymphocytic Leukemia Treated With BTK Inhibitors: A Propensity-Matched TriNetX Analysis

Jude Ossai

Poster Presenter: Jude Ossai

Thumbnail for Marrow-Dominant Aggressive Progression of TP53-Altered CLL/SLL After Reactive Myelofibrosis: A Diagnostic and Therapeutic Challenge

CLL - 620

Marrow-Dominant Aggressive Progression of TP53-Altered CLL/SLL After Reactive Myelofibrosis: A Diagnostic and Therapeutic Challenge

Adela Perolla

Poster Presenter: Adela Perolla

Thumbnail for Frequency and Factors Predisposing to Pulmonary Infections in Patients With Chronic Lymphocytic Leukemia Treated With Targeted Agents

CLL - 630

Frequency and Factors Predisposing to Pulmonary Infections in Patients With Chronic Lymphocytic Leukemia Treated With Targeted Agents

Maher Salamoon

Poster Presenter: Maher Salamoon

Thumbnail for Retreatment With Venetoclax-Based Therapies in Relapsed Chronic Lymphocytic Leukemia: A Pool Analysis of Outcomes Based on Treatment-Free Intervals and Cytogenetics/Molecular Risks

CLL - 662

Retreatment With Venetoclax-Based Therapies in Relapsed Chronic Lymphocytic Leukemia: A Pool Analysis of Outcomes Based on Treatment-Free Intervals and Cytogenetics/Molecular Risks

Jun Chih Wang

Poster Presenter: Jun Chih Wang